<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We present a 45-year-old male patient who presented to Accident and Emergency department with a 6-week history of pain and stiffness involving his bilateral legs </plain></SENT>
<SENT sid="1" pm="."><plain>Both calves were markedly tender, and he was not able to bear weight </plain></SENT>
<SENT sid="2" pm="."><plain>He also complained of numbness involving his left big toe for a few days, which later spread to involve his arms, and <z:hpo ids='HP_0000360'>tinnitus</z:hpo> and hearing loss in his left ear </plain></SENT>
<SENT sid="3" pm="."><plain>There were no respiratory, gastrointestinal or urinary symptoms </plain></SENT>
<SENT sid="4" pm="."><plain>He had a background history of <z:hpo ids='HP_0003124'>hypercholesterolemia</z:hpo> and was treated with <z:chebi fb="0" ids="39548">atorvastatin</z:chebi> 10 mg for 6 months </plain></SENT>
<SENT sid="5" pm="."><plain>His initial investigations showed markedly increased inflammatory markers, and serum antineutrophil cytoplasmic antibody (<z:chebi fb="0" ids="34507">ANCA</z:chebi>) was markedly positive at a titre of 1:160 (P-<z:chebi fb="0" ids="34507">ANCA</z:chebi>) </plain></SENT>
<SENT sid="6" pm="."><plain>Electromyography and muscle biopsy showed myopathic features </plain></SENT>
<SENT sid="7" pm="."><plain>A diagnosis of drug-induced <z:chebi fb="0" ids="34507">ANCA</z:chebi>-associated <z:hpo ids='HP_0002633'>vasculitis</z:hpo> (on the basis of <z:e sem="disease" ids="C0151295" disease_type="Disease or Syndrome" abbrv="">mononeuritis multiplex</z:e>, <z:mp ids='MP_0004740'>sensorineural hearing loss</z:mp> and markedly increased anti-myeloperoxidase (MPO) <z:chebi fb="0" ids="34507">ANCA</z:chebi>) and <z:chebi fb="0" ids="35664">statin</z:chebi>-induced distal <z:hpo ids='HP_0003198'>myopathy</z:hpo> was made </plain></SENT>
<SENT sid="8" pm="."><plain>He was treated with three 500 mg doses of <z:chebi fb="0" ids="6888">methylprednisolone</z:chebi>, followed by slowly tapering dose of oral <z:chebi fb="0" ids="50858">corticosteroids</z:chebi> from 30 mg once daily (OD) </plain></SENT>
<SENT sid="9" pm="."><plain>He was also started on azathioprin (2.5 mg/kg) </plain></SENT>
<SENT sid="10" pm="."><plain>He had a dramatic improvement of his <z:hpo ids='HP_0003326'>myalgia</z:hpo>, hearing loss and sensory symptoms and went into complete clinical remission </plain></SENT>
<SENT sid="11" pm="."><plain>His inflammatory markers rapidly returned to <z:mpath ids='MPATH_458'>normal</z:mpath>, and MPO-<z:chebi fb="0" ids="34507">ANCA</z:chebi> normalised within 3 months of starting immunosuppressive therapy and remained negative on further testing </plain></SENT>
<SENT sid="12" pm="."><plain>He is currently on a tapering regimen of <z:chebi fb="0" ids="50858">corticosteroids</z:chebi> (7 mg OD), and after weaning him off <z:chebi fb="0" ids="50858">corticosteroids</z:chebi>, we plan to slowly taper his azathioprin </plain></SENT>
</text></document>